Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Varinder Jeet"'
Autor:
Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson, Pamela J. Russell
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth,
Externí odkaz:
https://doaj.org/article/2ef2c8e3d8664d7a8617ef5010ba309f
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 14, p 3468 (2019)
The interleukin (IL)-20 subfamily of cytokines consists of IL-19, IL-20, IL-22, IL-24, and IL-26, and the expression of IL-20, IL-22, and IL-24 is reported to be higher in the colon of patients with ulcerative colitis. Although the receptors for thes
Externí odkaz:
https://doaj.org/article/dc13d201d4e1401ca91965a3c987aef5
Publikováno v:
PharmacoEconomics. 41:43-57
Publikováno v:
Value in Health Regional Issues. 32:17-22
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as a promising imaging tool in prostate cancer diagnosis. PSMA PET/CT radiotracers are produced in-house (gallium-68, eg,Hospitals and dia
Publikováno v:
PharmacoEconomics. 40:807-821
BACKGROUND AND OBJECTIVES: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) combined with computed tomography (CT) is a new imaging modality to detect the extra-prostatic spread of prostate cancer. PSMA PET/CT has a higher
Publikováno v:
Seminars in Nuclear Medicine.
Autor:
Varinder Jeet, Jonas Fooken
Publikováno v:
The European Journal of Health Economics. 23:717-728
Inequity in healthcare utilization is typically measured as the unequal distribution of services by observable non-need indicators, such as income, after controlling for observable need indicators. However, important sources of unequal healthcare uti
Autor:
Antonio Ahumada-Canale, Varinder Jeet, Anam Bilgrami, Elizabeth Seil, Yuanyuan Gu, Henry Cutler
Publikováno v:
Social Science & Medicine. 322:115790
Autor:
Pamela J. Russell, Bradley J. Walsh, Brian W.C. Tse, Mei-Chun Yeh, Varinder Jeet, Douglas Campbell, Nicholas L. Fletcher, Marianna Volpert, Chelsea Stewart, Maria E. Lund, Kristofer J. Thurecht, Kamil A. Sokolowski, Colleen C. Nelson, Zachary H. Houston
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-13 (2020)
EJNMMI Research
EJNMMI Research
PurposeChimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is o
Publikováno v:
Cancers
Volume 13
Issue 14
Cancers, Vol 13, Iss 3582, p 3582 (2021)
Volume 13
Issue 14
Cancers, Vol 13, Iss 3582, p 3582 (2021)
Background: Emerging evidence has revealed that genetic variations in microRNA (miRNA) binding sites called miRSNPs can alter miRNA binding in an allele-specific manner and impart prostate cancer (PCa) risk. Two miRSNPs, rs1530865 (G >
C) and
C) and